| Thea James, MD | |
|
1 Boston Medical Ctr Pl, Dowling 1 South, Boston, MA 02118-2908 | |
| (617) 414-5481 | |
| (617) 414-7759 |
| Full Name | Thea James |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 1 Boston Medical Ctr Pl, Boston, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164465043 | NPI | - | NPPES |
| J31288 | Other | MA | BCBS |
| 081539 | Other | MA | TUFTS |
| 3139841 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 81539 (Massachusetts) | Primary |
| Entity Name | Child Health Foundation Of Boston Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619969920 PECOS PAC ID: 1557263340 Enrollment ID: O20040122000712 |
News Archive
Cephalon, Inc. today announced that the company received a second Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the supplemental new drug application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV] for the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. In its letter to the company, the FDA reiterated its previously stated concerns regarding the NUVIGIL sNDA.
"Worm infestations, food parasites, Chagas disease, sand fly-transmitted infections and other neglected tropical diseases usually found in Africa and Asia are turning up more often in Europe, according to a new study" published recently in the International Journal of Infectious Diseases by researchers from the Sabin Vaccine Institute, the New York Times reports.
Impax Laboratories, Inc. today reported adjusted net revenue in the third quarter of 2010, excluding the effect of a change in accounting for revenue received under the Company's Strategic Alliance Agreement with Teva, increased $42.6 million to $107.6 million compared to the prior year period, driven by sales of generic Adderall XR for which there were no sales in the third quarter of 2009, as well as increased sales of the Company's fenofibrate products.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 4 days ago
| Entity Name | Boston Emergency Physician Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427005859 PECOS PAC ID: 4981596095 Enrollment ID: O20040325000554 |
News Archive
Cephalon, Inc. today announced that the company received a second Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the supplemental new drug application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV] for the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. In its letter to the company, the FDA reiterated its previously stated concerns regarding the NUVIGIL sNDA.
"Worm infestations, food parasites, Chagas disease, sand fly-transmitted infections and other neglected tropical diseases usually found in Africa and Asia are turning up more often in Europe, according to a new study" published recently in the International Journal of Infectious Diseases by researchers from the Sabin Vaccine Institute, the New York Times reports.
Impax Laboratories, Inc. today reported adjusted net revenue in the third quarter of 2010, excluding the effect of a change in accounting for revenue received under the Company's Strategic Alliance Agreement with Teva, increased $42.6 million to $107.6 million compared to the prior year period, driven by sales of generic Adderall XR for which there were no sales in the third quarter of 2009, as well as increased sales of the Company's fenofibrate products.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thea James, MD 720 Harrison Ave, Dob 503, Boston, MA 02118-2371 Ph: () - | Thea James, MD 1 Boston Medical Ctr Pl, Dowling 1 South, Boston, MA 02118-2908 Ph: (617) 414-5481 |
News Archive
Cephalon, Inc. today announced that the company received a second Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the supplemental new drug application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV] for the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. In its letter to the company, the FDA reiterated its previously stated concerns regarding the NUVIGIL sNDA.
"Worm infestations, food parasites, Chagas disease, sand fly-transmitted infections and other neglected tropical diseases usually found in Africa and Asia are turning up more often in Europe, according to a new study" published recently in the International Journal of Infectious Diseases by researchers from the Sabin Vaccine Institute, the New York Times reports.
Impax Laboratories, Inc. today reported adjusted net revenue in the third quarter of 2010, excluding the effect of a change in accounting for revenue received under the Company's Strategic Alliance Agreement with Teva, increased $42.6 million to $107.6 million compared to the prior year period, driven by sales of generic Adderall XR for which there were no sales in the third quarter of 2009, as well as increased sales of the Company's fenofibrate products.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 4 days ago
Yeu-shin Cindy Chang, M.D., M.P.H. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Bwh Dept. Of Emergency Medicine, Boston, MA 02115 Phone: 617-732-8070 | |
Lorenzo Albala, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 55 Fruit St, Boston, MA 02114 Phone: 617-724-4068 | |
Dr. Jacob Ari Hurwitz, MD MPH Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit St, Boston, MA 02114 Phone: 617-724-4068 | |
Christopher Lites, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 330 Brookline Ave, Boston, MA 02215 Phone: 617-667-7000 | |
Aneesh T Narang, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Boston Medical Ctr Pl, Dowling 1 South, Boston, MA 02118 Phone: 617-414-5481 Fax: 617-414-7759 | |
Dr. Justin Thomas Pitman, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Neville House - 236a, Boston, MA 02115 Phone: 617-732-8070 | |
Dr. Nadine Youssef, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 750 Washington St, Box 311 / Department Of Emergency Medicine, Boston, MA 02111 Phone: 617-636-4723 |